As indicated by earlier reports, ruthenium derivatives activate pro-apoptotic proteins of the Bcl-2 family (e.g., Bax) in cancer cells with high efficiency, while reducing the expression of anti-apoptotic Bcl-2. The gene discussed is BCL2; the disease is cancer.